Literature DB >> 8388907

Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward.

R A Karron1, K L O'Brien, J L Froehlich, V A Brown.   

Abstract

Parainfluenza type 3 virus (PIV-3), an important cause of acute lower respiratory illness in children, can be transmitted nosocomially. To differentiate between nosocomial transmission and community-acquired infection, a polymerase chain reaction-based sequencing assay was developed for the 5' noncoding region of the PIV-3 fusion protein gene and was applied to virus specimens from 10 children infected with PIV-3 during a hospital outbreak. Four strains of PIV-3 were identified among the 10 virus isolates. Six isolates, which appeared to belong to 1 strain, were obtained from a cluster of nosocomial cases in a pediatric intermediate care unit. In contrast, the remaining 4 isolates, which appeared to belong to 3 different strains, were obtained from children infected in the community or elsewhere in the hospital. These data indicate that multiple strains of PIV-3 can be found during a single epidemic and provide evidence that infections within the intermediate care unit were probably caused by transmission of 1 strain of virus within the unit rather than reintroduction of virus by new patients or staff.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388907     DOI: 10.1093/infdis/167.6.1441

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

2.  Simultaneous detection and identification of human parainfluenza viruses 1, 2, and 3 from clinical samples by multiplex PCR.

Authors:  J E Echevarría; D D Erdman; E M Swierkosz; B P Holloway; L J Anderson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Diagnosis of viral respiratory tract infections in children by using a reverse transcription-PCR panel.

Authors:  L L Gilbert; A Dakhama; B M Bone; E E Thomas; R G Hegele
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

4.  Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.

Authors:  H Laurichesse; D Dedman; J M Watson; M C Zambon
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

5.  The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Authors:  Ruth A Karron; Roberta Casey; Bhagvanji Thumar; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

6.  Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents.

Authors:  Susanne Meury; Sven Zeller; Ulrich Heininger
Journal:  Eur J Pediatr       Date:  2004-04-23       Impact factor: 3.183

7.  Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay.

Authors:  R A Karron; J L Froehlich; L Bobo; R B Belshe; R H Yolken
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 8.  Biology of parainfluenza viruses.

Authors:  R Vainionpää; T Hyypiä
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

9.  Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study.

Authors:  B Gröndahl; W Puppe; A Hoppe; I Kühne; J A Weigl; H J Schmitt
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Multicluster nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study.

Authors:  Antonio Piralla; Elena Percivalle; Alessandra Di Cesare-Merlone; Franco Locatelli; Giuseppe Gerna
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.